Company research / AWHL

Aspira Women's Health Inc. (AWHL)

CIK 0000926617 · OTC · In Vitro & In Vivo Diagnostic Substances

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Aspira Women's Health Inc. reported revenue of $9.22M. Revenue grew 0.4% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $8.55M.

Key ratios (year ended 2025-12-31)

64.2%
Gross margin
-85.9%
Operating margin
-138.7%
Net margin
0.4%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-10-02

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Stock splits: 1-for-15, first reflected in a filing dated 2023-05-15. Figures are as filed: per-share figures and share counts last reported before a split are on the old share basis, so changes and growth rates across a split are not shown. Splits are read from the filings' own restatements, so a share conversion in a merger or reorganization shows up the same way.

Period endedTTM to
2026-06-30
2025-12-312024-12-312023-12-312022-12-312022-09-302022-06-302022-03-312021-12-312020-12-312019-12-31
Revenue$8.55M$9.22M$9.18M$9.15Mn/an/an/an/an/an/an/a
Cost of Revenue$3.52M$3.30M$3.70M$3.89M$3.86Mn/an/an/a$3.75M$3.42M$3.34M
Gross Profit$5.02M$5.92M$5.48M$5.26M$4.32Mn/an/an/a$3.06M$1.24M$1.20M
R&D Expense$3.12M$2.88M$3.27M$4.04M$5.92Mn/an/an/a$5.31M$2.10M$1.02M
Operating Income-$6.90M-$7.91M-$16.28M-$18.85M-$31.14Mn/an/an/a-$32.59M-$17.98M-$15.28M
Depreciation & Amortization$168.0K$112.0K$92.0K$199.0K$264.0Kn/an/an/a$302.0K$265.0K$333.0K
EBITDA-$6.73M-$7.80M-$16.19M-$18.65M-$30.87Mn/an/an/a-$32.29M-$17.72M-$14.95M
Net Income-$10.01M-$12.78M-$13.09M-$16.69M-$29.89Mn/an/an/a-$31.66M-$17.91M-$15.24M
EPS (Diluted)n/a-$0.37-$0.93-$1.81-$3.85n/an/an/a-$4.27-$0.18-$0.18
Total Assets$4.43M$5.46M$5.49M$6.26M$17.37M$23.94Mn/an/a$41.08M$19.61M$13.83M
Total Liabilities$11.69M$12.39M$8.05M$8.63M$10.39M$12.76Mn/an/a$10.91M$9.89M$5.09M
Long-Term Debt$1.16M$1.28M$1.51M$1.60M$2.72Mn/an/an/a$2.92M$4.12M$1.29M
Shareholders' Equity-$7.26M-$6.93M-$2.56M-$2.37M$6.98M$11.18M$14.12M$21.74M$30.17M$9.72M$8.74M
Cash & Equivalents$477.0K$1.75M$1.77M$2.60M$13.31M$20.55Mn/an/a$37.18M$16.63Mn/a
Operating Cash Flow-$4.56M-$7.03M-$12.11M-$15.89M-$31.07Mn/an/an/a-$27.39M-$14.73M-$12.96M
Capital Expendituresn/a$16.0K$37.0K$24.0K$232.0Kn/an/an/a$184.0K$490.0K$133.0K
Free Cash Flown/a-$7.04M-$12.15M-$15.92M-$31.30Mn/an/an/a-$27.58M-$15.22M-$13.10M
Shares Outstanding46.63M43.48M17.41M10.65M8.31M8.30Mn/an/a7.48M104.62M97.29M
Weighted Average Diluted Sharesn/a34.10M14.13M9.23M7.77Mn/an/an/a7.41M100.72M86.60M
EPS (Basic)n/a-$0.37-$0.93-$1.81-$3.85n/an/an/a-$4.27-$0.18-$0.18